按下贪睡按钮：使用FLT3抑制剂quizartinib诱导静止状态可保护造血祖细胞免受化疗影响。
Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.
作者信息
Taylor Samuel J, Langdon Wallace Y
机构信息
Department of Pathology and Laboratory Medicine, School of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
出版信息
Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017.
Abstract
Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).
摘要
骨髓抑制是化疗最严重且具有限制性的副作用之一。我们最近的研究概述了一种通过给予初始剂量的FMS样酪氨酸激酶3（FLT3）抑制剂奎扎替尼来预防化疗诱导的骨髓抑制的策略。此外，通过连续给予经奎扎替尼预处理的氟尿嘧啶（5-FU）注射，我们在两种奎扎替尼耐药的急性髓系白血病（AML）小鼠模型中证明了一种消除疾病的新颖且有效的策略。
相似文献
1
Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.按下贪睡按钮：使用FLT3抑制剂quizartinib诱导静止状态可保护造血祖细胞免受化疗影响。
Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017.
2
Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.通过重新利用 FLT3 抑制剂 quizartinib 预防化疗引起的骨髓抑制。
Sci Transl Med. 2017 Aug 9;9(402). doi: 10.1126/scitranslmed.aam8060.
3
Quizartinib (AC220): a promising option for acute myeloid leukemia.喹扎替尼（AC220）：急性髓系白血病的一个有前景的选择。
Drug Des Devel Ther. 2019 Apr 8;13:1117-1125. doi: 10.2147/DDDT.S198950. eCollection 2019.
4
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.Quizartinib 与挽救性化疗治疗复发或难治性 FLT3-ITD 急性髓系白血病（QuANTUM-R）：一项多中心、随机、对照、开放标签、3 期临床试验。
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
5
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.一项关于 Quizartinib 联合化疗治疗复发儿童白血病的 I 期研究：儿童白血病与淋巴瘤治疗进展（TACL）研究。
Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26.
6
The role of quizartinib in the treatment of acute myeloid leukemia.夸替替尼在急性髓系白血病治疗中的作用。
Expert Opin Investig Drugs. 2013 Dec;22(12):1659-69. doi: 10.1517/13543784.2013.842973. Epub 2013 Sep 26.
7
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.Quizartinib 治疗复发/难治性 FLT3-ITD 急性髓系白血病的实用考虑：实例报告。
Clin Drug Investig. 2020 Mar;40(3):227-235. doi: 10.1007/s40261-019-00881-7.
8
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.在一项 1 期研究中，评估 quizartinib 在复发或难治性急性髓系白血病的日本患者中的安全性和药代动力学。
Int J Hematol. 2019 Dec;110(6):654-664. doi: 10.1007/s12185-019-02709-8. Epub 2019 Jul 29.
9
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.quizartinib是一种选择性FLT3抑制剂，在RAS介导的米哚妥林耐药急性髓系白血病细胞的临床前模型中维持抗白血病活性。
Oncotarget. 2020 Mar 17;11(11):943-955. doi: 10.18632/oncotarget.27489.
10
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date.Quizartinib治疗复发/难治性FLT3-ITD阳性急性髓系白血病成年患者的概况：迄今的证据
Cancer Manag Res. 2020 Jan 8;12:151-163. doi: 10.2147/CMAR.S196568. eCollection 2020.
本文引用的文献
1
Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.通过重新利用 FLT3 抑制剂 quizartinib 预防化疗引起的骨髓抑制。
Sci Transl Med. 2017 Aug 9;9(402). doi: 10.1126/scitranslmed.aam8060.
2
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.短暂抑制CDK4/6可保护造血干细胞免受化疗诱导的耗竭。
Sci Transl Med. 2017 Apr 26;9(387). doi: 10.1126/scitranslmed.aal3986.
3
An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.一项在健康男性受试者中进行的开放标签、单剂量1期研究，旨在研究用于治疗急性髓性白血病的高度选择性强效FLT3酪氨酸激酶抑制剂quizartinib的吸收、代谢和排泄情况。
Xenobiotica. 2017 Oct;47(10):856-869. doi: 10.1080/00498254.2016.1217100. Epub 2017 Jul 25.
4
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.克服针对FLT3的急性髓系白血病治疗中因合成致死毒性导致的骨髓抑制。
Elife. 2014 Dec 22;3:e03445. doi: 10.7554/eLife.03445.
5
Antineoplastic agents and the associated myelosuppressive effects: a review.抗肿瘤药物及其相关的骨髓抑制作用：综述
J Pharm Pract. 2014 Oct;27(5):440-6. doi: 10.1177/0897190014546108. Epub 2014 Aug 20.
6
Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.Flt3 抑制剂 AC220 是一种有效的治疗方法，可用于由增强的野生型 Flt3 信号驱动的骨髓增生性疾病的小鼠模型。
Blood. 2012 Nov 8;120(19):4049-57. doi: 10.1182/blood-2012-06-436675. Epub 2012 Sep 18.
7
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).AC220是一种独特的强效且选择性的FLT3抑制剂，用于治疗急性髓系白血病（AML）。
Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4.
Zotero 插件